STOCK TITAN

[Form 4] HERON THERAPEUTICS, INC. /DE/ Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Heron Therapeutics (HRTX) — insider activity reported. Rubric Capital Management LP and David Rosen filed a Form 4. On 10/15/2025, 94,610 Series A preferred shares automatically converted into 946,100 common shares at a $1.50 conversion price. After this, 30,046,828 common shares were beneficially owned indirectly.

The filing also lists $35,000,000 of Convertible Senior Unsecured Notes, convertible after December 31, 2025, maturing on March 1, 2031, with a conversion rate of 555.5556 per $1,000 principal and 5.0% cash interest (with a right to pay certain interest in new notes at 7.0% before September 1, 2026).

Heron Therapeutics (HRTX) — attività d'insider riportata. Rubric Capital Management LP e David Rosen hanno presentato un Form 4. Il 15/10/2025, 94.610 azioni privilegiate di Serie A si sono automaticamente convertite in 946.100 azioni ordinarie al prezzo di conversione di 1,50 $. Dopo questa operazione, 30.046.828 azioni ordinarie erano possedute indirettamente a titolo beneficiario.

La dichiarazione segnala anche 35.000.000 $ di Note Convertibili Senior Non Garantite, convertibili dopo il 31 dicembre 2025, con scadenza il 1 marzo 2031, con un tasso di conversione di 555,5556 per 1.000 di capitale e un interesse in contanti del 5,0% (con diritto di pagare parte degli interessi in nuove obbligazioni al 7,0% prima del 1 settembre 2026).

Heron Therapeutics (HRTX) — actividad de insiders reportada. Rubric Capital Management LP y David Rosen presentaron un Form 4. El 15/10/2025, 94.610 acciones preferentes de Serie A se convirtieron automáticamente en 946.100 acciones ordinarias a un precio de conversión de 1,50 $. Después de esto, 30.046.828 acciones ordinarias fueron poseídas de forma beneficiosa indirectamente.

La declaración también indica 35.000.000 $ de Notas Convertibles Senior No Garantizadas, convertibles después del 31 de diciembre de 2025, vencimiento el 1 de marzo de 2031, con una tasa de conversión de 555,5556 por 1.000 de principal y un interés en efectivo del 5,0% (con derecho a pagar ciertos intereses en nuevas notas al 7,0% antes del 1 de septiembre de 2026).

Heron Therapeutics (HRTX) — 내부자 거래 활동이 보고되었습니다. Rubric Capital Management LP와 David Rosen이 Form 4를 제출했습니다. 2025년 10월 15일94,610주 시리즈 A 우선주가 자동으로 946,100주 보통주로 전환되었으며 전환가액은 1.50달러였습니다. 그 후 30,046,828주 보통주가 간접적으로 수익 소유로 보유되었습니다.

또한 제출서에는 35,000,000달러의 전환가능 상환우선채권(Convertible Senior Unsecured Notes)이 기입되어 있으며, 이는 2025년 12월 31일 이후로 전환 가능하고 만기는 2031년 3월 1일, 주 채권액 1,000달러당 555.5556의 전환비율 및 5.0%의 현금 이자(2026년 9월 1일 이전에 7.0%의 새로운 채권으로 일부 이자를 지급할 권리가 있음)가 적용됩니다.

Heron Therapeutics (HRTX) — activité d'initiés signalée. Rubric Capital Management LP et David Rosen ont déposé un Form 4. Le 15/10/2025, 94 610 actions privilégiées de série A ont été automatiquement converties en 946 100 actions ordinaires à un prix de conversion de 1,50 $. Après cela, 30 046 828 actions ordinaires étaient détenues bénéficiairement de manière indirecte.

La déclaration répertorie également 35 000 000 de notes seniors non garanties convertibles, convertibles après le 31 décembre 2025, arrivant à échéance le 1er mars 2031, avec un taux de conversion de 555,5556 pour 1 000 de principal et un intérêt en espèces de 5,0% (avec droit de payer certains intérêts en nouvelles obligations à 7,0% avant le 1er septembre 2026).

Heron Therapeutics (HRTX) — Insideraktivität gemeldet. Rubric Capital Management LP und David Rosen haben ein Formular 4 eingereicht. Am 15.10.2025 wurden 94.610 Serie-A-Vorzugsaktien automatisch in 946.100 Stammaktien zum Umtauschpreis von 1,50 $ umgewandelt. Danach waren 30.046.828 Stammaktien indirekt im Eigentum vorteilhaft gehalten.

Die Anmeldung listet außerdem 35.000.000 Wandelanleihen (Convertible Senior Unsecured Notes), nach 31.12.2025 wandelbar, fällig am 01.03.2031, mit einem Umtauschverhältnis von 555,5556 pro 1.000 Nennwert und einem Barzins von 5,0% (mit dem Recht, bestimmte Zinsen in neue Anleihen zu 7,0% vor dem 01.09.2026 zu zahlen).

هيرون ثيرابيوتيكس (HRTX) — تم الإبلاغ عن نشاط من المطلعين. قدمت Rubric Capital Management LP وDavid Rosen نموذج Form 4. في 15/10/2025، تحولت 94,610 أسهم تفضيلية من الفئة أ تلقائيًا إلى 946,100 سهمًا عاديًا بسعر تحويل قدره 1.50 دولار. بعد ذلك، كانت 30,046,828 من الأسهم العادية مملوكة بشكل مفيد بشكل غير مباشر.

كما يتضمن البيان أيضًا 35,000,000$ من Notes Convertibles Senior Unsecured، قابلة للتحويل بعد 31 ديسمبر 2025، وتاريخ الاستحقاق في 1 مارس 2031، بمعدل تحويل قدره 555.5556 لكل 1,000 من الأصل و فائدة نقدية قدرها 5.0% (مع حق دفع بعض الفوائد في سندات جديدة بسعر 7.0% قبل 1 سبتمبر 2026).

Heron Therapeutics (HRTX) — 内幕交易活动已报告。 Rubric Capital Management LP 与 David Rosen 提交了 Form 4。于 2025/10/1594,610 股 A 轮优先股自动转换为 946,100 股普通股,转换价格为 1.50 美元。在此之后,30,046,828 股普通股通过间接方式受益所有权的方式持有。

备案还列出 35,000,000 美元的可转换高级无担保票据(Convertible Senior Unsecured Notes),在 2025年12月31日以后可转换,期限至 2031年3月1日,每 1,000 美元本金的转换比率为 555.5556,现金利率为 5.0%(在 2026/9/1 前有权以新票据支付部分利息,利率为 7.0%)。

Positive
  • None.
Negative
  • None.

Heron Therapeutics (HRTX) — attività d'insider riportata. Rubric Capital Management LP e David Rosen hanno presentato un Form 4. Il 15/10/2025, 94.610 azioni privilegiate di Serie A si sono automaticamente convertite in 946.100 azioni ordinarie al prezzo di conversione di 1,50 $. Dopo questa operazione, 30.046.828 azioni ordinarie erano possedute indirettamente a titolo beneficiario.

La dichiarazione segnala anche 35.000.000 $ di Note Convertibili Senior Non Garantite, convertibili dopo il 31 dicembre 2025, con scadenza il 1 marzo 2031, con un tasso di conversione di 555,5556 per 1.000 di capitale e un interesse in contanti del 5,0% (con diritto di pagare parte degli interessi in nuove obbligazioni al 7,0% prima del 1 settembre 2026).

Heron Therapeutics (HRTX) — actividad de insiders reportada. Rubric Capital Management LP y David Rosen presentaron un Form 4. El 15/10/2025, 94.610 acciones preferentes de Serie A se convirtieron automáticamente en 946.100 acciones ordinarias a un precio de conversión de 1,50 $. Después de esto, 30.046.828 acciones ordinarias fueron poseídas de forma beneficiosa indirectamente.

La declaración también indica 35.000.000 $ de Notas Convertibles Senior No Garantizadas, convertibles después del 31 de diciembre de 2025, vencimiento el 1 de marzo de 2031, con una tasa de conversión de 555,5556 por 1.000 de principal y un interés en efectivo del 5,0% (con derecho a pagar ciertos intereses en nuevas notas al 7,0% antes del 1 de septiembre de 2026).

Heron Therapeutics (HRTX) — 내부자 거래 활동이 보고되었습니다. Rubric Capital Management LP와 David Rosen이 Form 4를 제출했습니다. 2025년 10월 15일94,610주 시리즈 A 우선주가 자동으로 946,100주 보통주로 전환되었으며 전환가액은 1.50달러였습니다. 그 후 30,046,828주 보통주가 간접적으로 수익 소유로 보유되었습니다.

또한 제출서에는 35,000,000달러의 전환가능 상환우선채권(Convertible Senior Unsecured Notes)이 기입되어 있으며, 이는 2025년 12월 31일 이후로 전환 가능하고 만기는 2031년 3월 1일, 주 채권액 1,000달러당 555.5556의 전환비율 및 5.0%의 현금 이자(2026년 9월 1일 이전에 7.0%의 새로운 채권으로 일부 이자를 지급할 권리가 있음)가 적용됩니다.

Heron Therapeutics (HRTX) — activité d'initiés signalée. Rubric Capital Management LP et David Rosen ont déposé un Form 4. Le 15/10/2025, 94 610 actions privilégiées de série A ont été automatiquement converties en 946 100 actions ordinaires à un prix de conversion de 1,50 $. Après cela, 30 046 828 actions ordinaires étaient détenues bénéficiairement de manière indirecte.

La déclaration répertorie également 35 000 000 de notes seniors non garanties convertibles, convertibles après le 31 décembre 2025, arrivant à échéance le 1er mars 2031, avec un taux de conversion de 555,5556 pour 1 000 de principal et un intérêt en espèces de 5,0% (avec droit de payer certains intérêts en nouvelles obligations à 7,0% avant le 1er septembre 2026).

Heron Therapeutics (HRTX) — Insideraktivität gemeldet. Rubric Capital Management LP und David Rosen haben ein Formular 4 eingereicht. Am 15.10.2025 wurden 94.610 Serie-A-Vorzugsaktien automatisch in 946.100 Stammaktien zum Umtauschpreis von 1,50 $ umgewandelt. Danach waren 30.046.828 Stammaktien indirekt im Eigentum vorteilhaft gehalten.

Die Anmeldung listet außerdem 35.000.000 Wandelanleihen (Convertible Senior Unsecured Notes), nach 31.12.2025 wandelbar, fällig am 01.03.2031, mit einem Umtauschverhältnis von 555,5556 pro 1.000 Nennwert und einem Barzins von 5,0% (mit dem Recht, bestimmte Zinsen in neue Anleihen zu 7,0% vor dem 01.09.2026 zu zahlen).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rubric Capital Management LP

(Last) (First) (Middle)
155 EAST 44TH ST, SUITE 1630

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.01 per share ("Common Stock") 10/15/2025 C 946,100 A (1) 30,046,828 I See footnotes(2)(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Convertible Preferred Stock ("Preferred Shares") (1) 10/15/2025 C 94,610 (1) (1) Common Stock 946,100 $0 0 I See footnotes(2)(3)
Convertible Senior Unsecured Promissory Notes ("Notes")(4) (5) (6) (6) See footnote(5) (5) $35,000,000 I See footnotes(2)(3)
1. Name and Address of Reporting Person*
Rubric Capital Management LP

(Last) (First) (Middle)
155 EAST 44TH ST, SUITE 1630

(Street)
NEW YORK NY 10017

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Rosen David Efraim

(Last) (First) (Middle)
155 EAST 44TH ST., SUITE 1630

(Street)
NEW YORK NY 10017

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The Preferred Shares automatically converted into Common Stock pursuant to their terms at a conversion price of $1.50.
2. This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital.
3. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
4. The Notes are restated here to correct the maturity date thereof as reported in the Form 4 filed by the Reporting Persons on August 12, 2025.
5. The Notes convert at an initial conversion rate of 555.5556 per $1,000 principal amount of Notes, subject to adjustment as set forth in that certain Note Purchase Agreement, dated as of August 8, 2025, by and between the Company, the purchasers from time to time party hereto, and Rubric Capital Management LP, as agent for the purchasers. Conversions of the Notes are settled, at the election of the Company, in cash, shares of Common Stock, or a combination of cash and shares of Common Stock. The Notes bear cash interest at a rate of 5.0% per year until maturity, provided that the Company has the right to pay all accrued and unpaid interest prior to September 1, 2026 in new Notes at a rate of 7.0% per year.
6. The Notes are convertible after December 31, 2025. The Notes mature on March 1, 2031.
Rubric Capital Management LP, By: /s/ Michael Nachmani, its Chief Operating Officer 10/17/2025
/s/ David Rosen 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rubric Capital report in the HRTX Form 4?

On 10/15/2025, 94,610 Series A preferred shares converted into 946,100 common shares at $1.50 per share.

How many HRTX shares were beneficially owned after the transaction?

The filing shows 30,046,828 common shares beneficially owned indirectly following the reported conversion.

Who are the reporting persons in this HRTX Form 4?

Rubric Capital Management LP and David Rosen, with indirect ownership via Rubric-managed vehicles.

What are the key terms of the HRTX convertible notes listed?

Principal $35,000,000; convertible after Dec 31, 2025; maturity Mar 1, 2031; conversion rate 555.5556 per $1,000; interest 5.0% cash (option to pay certain interest at 7.0% in new notes before Sep 1, 2026).

Was the conversion price for the preferred-to-common conversion disclosed?

Yes. The preferred shares automatically converted at a $1.50 conversion price, per the security’s terms.

Is the ownership direct or indirect?

The Form 4 indicates indirect ownership, with details referenced in the footnotes.
Heron Therapeutics Inc

NASDAQ:HRTX

HRTX Rankings

HRTX Latest News

HRTX Latest SEC Filings

HRTX Stock Data

238.31M
179.97M
0.74%
87.88%
21.13%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO